title: Solanezumab: too late in mild Alzheimer's disease?
authors.lastname: The Lancet Neurology
mesh_terms: D000544:Alzheimer Disease / Q000175:diagnosis* / Q000188:drug therapy*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C550616:solanezumab